OBJECTIVE: Intrathecal methotrexate (MTX) therapy combined with whole brain radiotherapy (WBRT) is one of the major treatment modalities for leukemia and lymphoma involving the central nervous system (CNS). The purpose of this study was to retrospectively determine the incidences of leukoencephalopathy and disseminated necrotizing leukoencephalopathy (DNL) following intrathecal MTX therapy for CNS lymphoma or leukemia and to assess the potential risk factors. METHODS: Between January 2000 and August 2009, 143 patients with CNS lymphoma or leukemia received intrathecal MTX therapy alone or in combination with WBRT at a single institution. Patients were followed up clinically and radiologically at regular two- or three-month intervals. Medical records were reviewed to obtain information regarding the patients' demographics, medical histories, radiologic characteristics, treatments, and clinical courses. RESULTS: On follow-up MR images, leukoencephalopathy was found in 95 of 143 patients (66.4%). The median time to develop leukoencephalopathy was 6.6 months. Among those with leukoencephalopathy, four patients showed seven extensive white-matter changes with strongly enhancing lesions demonstrating DNL. Histological confirmation was done in six lesions of three patients and radiological diagnosis alone in one patient. Four lesions spontaneously disappeared on MR images without any treatment, with a mean duration of 14 months before disappearance of DNL. CONCLUSION: Leukoencephalopathy is a common phenomenon that occurs following intrathecal MTX therapy; however, DNL occurs at a very low incidence. For newly developed enhancing lesions, consideration for the occurrence of DNL should be taken to avoid unnecessary invasive procedures or therapies.
OBJECTIVE: Intrathecal methotrexate (MTX) therapy combined with whole brain radiotherapy (WBRT) is one of the major treatment modalities for leukemia and lymphoma involving the central nervous system (CNS). The purpose of this study was to retrospectively determine the incidences of leukoencephalopathy and disseminated necrotizing leukoencephalopathy (DNL) following intrathecal MTX therapy for CNS lymphoma or leukemia and to assess the potential risk factors. METHODS: Between January 2000 and August 2009, 143 patients with CNS lymphoma or leukemia received intrathecal MTX therapy alone or in combination with WBRT at a single institution. Patients were followed up clinically and radiologically at regular two- or three-month intervals. Medical records were reviewed to obtain information regarding the patients' demographics, medical histories, radiologic characteristics, treatments, and clinical courses. RESULTS: On follow-up MR images, leukoencephalopathy was found in 95 of 143 patients (66.4%). The median time to develop leukoencephalopathy was 6.6 months. Among those with leukoencephalopathy, four patients showed seven extensive white-matter changes with strongly enhancing lesions demonstrating DNL. Histological confirmation was done in six lesions of three patients and radiological diagnosis alone in one patient. Four lesions spontaneously disappeared on MR images without any treatment, with a mean duration of 14 months before disappearance of DNL. CONCLUSION:Leukoencephalopathy is a common phenomenon that occurs following intrathecal MTX therapy; however, DNL occurs at a very low incidence. For newly developed enhancing lesions, consideration for the occurrence of DNL should be taken to avoid unnecessary invasive procedures or therapies.
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: Hendrik Pels; Ingo G H Schmidt-Wolf; Axel Glasmacher; Holger Schulz; Andreas Engert; Volker Diehl; Anton Zellner; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Martina Deckert; Rolf Fimmers; Christoph Helmstaedter; Aslihan Atasoy; Thomas Klockgether; Uwe Schlegel Journal: J Clin Oncol Date: 2003-11-03 Impact factor: 44.544
Authors: Meltem Ekenel; Fabio M Iwamoto; Leah S Ben-Porat; Katherine S Panageas; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Rolf-Dieter Kortmann; Beate Timmermann; Roger E Taylor; Giovanni Scarzello; Ludwig Plasswilm; Frank Paulsen; Branislav Jeremic; Astrid K Gnekow; Karin Dieckmann; Sylvia Kay; Michael Bamberg Journal: Strahlenther Onkol Date: 2003-09 Impact factor: 3.621
Authors: Daniel F Marker; Julia K Kofler; Joseph A Mettenburg; Mounzer E Agha; Clayton A Wiley Journal: J Neuropathol Exp Neurol Date: 2020-10-01 Impact factor: 3.685
Authors: Brian J Scott; Vincent A van Vugt; Toni Rush; Tiffany Brown; Clark C Chen; Bob S Carter; Richard Schwab; Paul Fanta; Teresa Helsten; Lyudmila Bazhenova; Barbara Parker; Sandeep Pingle; Marlon G Saria; Bradley D Brown; David E Piccioni; Santosh Kesari Journal: J Neurooncol Date: 2014-06-19 Impact factor: 4.130
Authors: Rimas V Lukas; Jigisha P Thakkar; Massimo Cristofanilli; Sunandana Chandra; Jeffrey A Sosman; Jyoti D Patel; Priya Kumthekar; Roger Stupp; Maciej S Lesniak Journal: J Neurooncol Date: 2022-01-20 Impact factor: 4.130
Authors: Ninh Doan; Mohit Patel; Ha Son Nguyen; Hayley Doan; Saman Shabani; Michael Gelsomino; Andrew Mountoure; Karl Janich; Christopher R Chitambar Journal: Asian J Neurosurg Date: 2018 Jul-Sep